Literature DB >> 16129588

Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.

Cornelia M Keck1, Rainer H Müller.   

Abstract

For many new chemical entities (NCE) of very low solubility oral bioavailability enhancement by micronisation is not sufficient, the next step taken was nanonisation. The production of drug nanocrystals by bottom up techniques (precipitation) is briefly described, main focus is given on particle diminution by high pressure homogenisation. Homogenisation can be performed in water (DissoCubes) or alternatively in non-aqueous media or water-reduced media (Nanopure). There is also a combination process of precipitation followed by a second high energy step, e.g. homogenisation (NANOEDGE). The result is a suspension of drug nanocrystals in a liquid, the so-called nanosuspension. Presented are the physical background of the diminution process, effects of production parameters (power density, number of homogenisation cycles) on crystal size, clinical batch production and scaling up of the production. As an important point the transfer of the liquid nanosuspensions to patient convenient oral dosage forms such as tablets and capsules is described.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16129588     DOI: 10.1016/j.ejpb.2005.05.009

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  109 in total

1.  Development and characterisation of ursolic acid nanocrystals without stabiliser having improved dissolution rate and in vitro anticancer activity.

Authors:  Ju Song; Yancai Wang; Yuelin Song; Hokman Chan; Chao Bi; Xiao Yang; Ru Yan; Yitao Wang; Ying Zheng
Journal:  AAPS PharmSciTech       Date:  2014-02       Impact factor: 3.246

Review 2.  Oral bioavailability: issues and solutions via nanoformulations.

Authors:  Kamla Pathak; Smita Raghuvanshi
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

Review 3.  Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.

Authors:  William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

4.  Evaluation of tadalafil nanosuspensions and their PEG solid dispersion matrices for enhancing its dissolution properties.

Authors:  Wasfy M Obeidat; Al-Sayed A Sallam
Journal:  AAPS PharmSciTech       Date:  2014-01-09       Impact factor: 3.246

5.  Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation.

Authors:  Peng Quan; Dengning Xia; Hongze Piao; Hongyu Piao; Kai Shi; Yinnong Jia; Fude Cui
Journal:  AAPS PharmSciTech       Date:  2011-09-03       Impact factor: 3.246

6.  An Intensified Vibratory Milling Process for Enhancing the Breakage Kinetics during the Preparation of Drug Nanosuspensions.

Authors:  Meng Li; Lu Zhang; Rajesh N Davé; Ecevit Bilgili
Journal:  AAPS PharmSciTech       Date:  2015-07-17       Impact factor: 3.246

7.  Using USP I and USP IV for discriminating dissolution rates of nano- and microparticle-loaded pharmaceutical strip-films.

Authors:  Lucas Sievens-Figueroa; Natasha Pandya; Anagha Bhakay; Golshid Keyvan; Bozena Michniak-Kohn; Ecevit Bilgili; Rajesh N Davé
Journal:  AAPS PharmSciTech       Date:  2012-10-23       Impact factor: 3.246

8.  Active curcumin nanoparticles formed from a volatile microemulsion template.

Authors:  K Margulis; S Srinivasan; M J Ware; H D Summers; B Godin; S Magdassi
Journal:  J Mater Chem B       Date:  2014       Impact factor: 6.331

9.  Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: elucidation of the mechanism by in-line Raman spectroscopy.

Authors:  Hans de Waard; Thomas De Beer; Wouter L J Hinrichs; Chris Vervaet; Jean-Paul Remon; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-07-13       Impact factor: 4.009

Review 10.  Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs.

Authors:  Lei Gao; Guiyang Liu; Jianli Ma; Xiaoqing Wang; Liang Zhou; Xiang Li; Fang Wang
Journal:  Pharm Res       Date:  2012-10-17       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.